NO2760821T3 - - Google Patents

Info

Publication number
NO2760821T3
NO2760821T3 NO12780535A NO12780535A NO2760821T3 NO 2760821 T3 NO2760821 T3 NO 2760821T3 NO 12780535 A NO12780535 A NO 12780535A NO 12780535 A NO12780535 A NO 12780535A NO 2760821 T3 NO2760821 T3 NO 2760821T3
Authority
NO
Norway
Application number
NO12780535A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2760821T3 publication Critical patent/NO2760821T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO12780535A 2014-01-31 2012-08-31 NO2760821T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461933948P 2014-01-31 2014-01-31

Publications (1)

Publication Number Publication Date
NO2760821T3 true NO2760821T3 (cg-RX-API-DMAC10.html) 2018-03-10

Family

ID=52484569

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12780535A NO2760821T3 (cg-RX-API-DMAC10.html) 2014-01-31 2012-08-31

Country Status (24)

Country Link
US (3) US20170057961A1 (cg-RX-API-DMAC10.html)
EP (1) EP3099688B1 (cg-RX-API-DMAC10.html)
JP (1) JP6419836B2 (cg-RX-API-DMAC10.html)
CN (1) CN106459051B (cg-RX-API-DMAC10.html)
AR (1) AR099228A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016016741B1 (cg-RX-API-DMAC10.html)
CA (1) CA2937738C (cg-RX-API-DMAC10.html)
CY (1) CY1120534T1 (cg-RX-API-DMAC10.html)
DK (1) DK3099688T3 (cg-RX-API-DMAC10.html)
EA (1) EA032650B1 (cg-RX-API-DMAC10.html)
ES (1) ES2655540T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20172002T1 (cg-RX-API-DMAC10.html)
HU (1) HUE038060T2 (cg-RX-API-DMAC10.html)
LT (1) LT3099688T (cg-RX-API-DMAC10.html)
MX (1) MX2016009385A (cg-RX-API-DMAC10.html)
NO (1) NO2760821T3 (cg-RX-API-DMAC10.html)
PL (1) PL3099688T3 (cg-RX-API-DMAC10.html)
PT (1) PT3099688T (cg-RX-API-DMAC10.html)
RS (1) RS56785B1 (cg-RX-API-DMAC10.html)
SI (1) SI3099688T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201800024T1 (cg-RX-API-DMAC10.html)
TW (1) TWI703144B (cg-RX-API-DMAC10.html)
UY (1) UY35972A (cg-RX-API-DMAC10.html)
WO (1) WO2015116882A1 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
ES2893251T3 (es) 2014-01-31 2022-02-08 Bristol Myers Squibb Co Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa
NO2760821T3 (cg-RX-API-DMAC10.html) 2014-01-31 2018-03-10
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (cg-RX-API-DMAC10.html) * 2014-10-01 2018-10-20
WO2016205482A1 (en) 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
WO2017019821A1 (en) 2015-07-29 2017-02-02 Bristol-Myers Squibb Company Factor xia new macrocycle bearing a non-aromatic p2' group
EP3328851B1 (en) 2015-07-29 2020-04-22 Bristol-Myers Squibb Company Factor xia macrocyclic inhibitors bearing alkyl or cycloalkyl p2' moieties
US10214512B2 (en) * 2015-10-29 2019-02-26 Merck Sharp & Dohme Corp. Factor XIA inhibitors
US10344039B2 (en) 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
EP3423458A1 (en) 2016-03-02 2019-01-09 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
CN110248938A (zh) 2016-11-23 2019-09-17 拜耳作物科学股份公司 用作农药的2-[3-(烷基磺酰基)-2h-吲唑-2-基]-3h-咪唑并[4,5-b]吡啶衍生物和类似化合物
WO2018130437A1 (de) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
JP7098630B2 (ja) 2017-01-10 2022-07-11 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体
WO2018133793A1 (zh) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
CN110922412A (zh) * 2018-09-20 2020-03-27 复旦大学 具有抗精神病作用药物化合物的不对称合成方法
US12018027B2 (en) 2019-04-16 2024-06-25 China Resources Biopharmaceutical Company Limited Macrocyclic derivatives acting as XIa factor inhibitor
CN114341714A (zh) * 2019-07-08 2022-04-12 加里夏普创新有限责任公司 具有高对比度的紧凑型基于偏振的准直器
CN114008047B (zh) * 2019-07-23 2023-03-21 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法
CN117603208A (zh) * 2021-04-21 2024-02-27 上海美悦生物科技发展有限公司 FXIa抑制剂及其药物组合物、制备方法和用途
CN119894901A (zh) * 2023-06-30 2025-04-25 深圳信立泰药业股份有限公司 一种多取代的大环化合物及其制备方法与应用

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525186A (fr) 1967-03-29 1968-05-17 Roussel Uclaf Nouvelles pénicillines et procédé de préparation
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US5624936A (en) 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996034010A2 (en) 1995-03-29 1996-10-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507597A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼ阻害剤
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
EP2261235A3 (en) 1998-03-19 2011-04-20 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
KR20010043829A (ko) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
EP1016663A1 (en) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
TR200101903T2 (tr) 1999-01-02 2001-11-21 Aventis Pharma Deutschland Gmbh Yeni malonik asit türevleri, bunların preparasyon işlemleri.
ATE281466T1 (de) 1999-04-09 2004-11-15 Abbott Gmbh & Co Kg Niedermolekulare inhibitoren von komplementproteasen
AU5413600A (en) 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
ES2252230T3 (es) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
WO2003011222A2 (en) 2001-07-27 2003-02-13 Merck & Co., Inc. Thrombin inhibitors
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
CN101357914A (zh) 2001-09-21 2009-02-04 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
WO2003041641A2 (en) 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2003106438A1 (en) 2002-06-18 2003-12-24 The Scripps Research Institute Synthesis of diazonamide "a" core
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
CA2531796A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
EP1841504B1 (en) 2005-01-13 2014-11-19 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
WO2007047608A2 (en) 2005-10-14 2007-04-26 Epix Pharmaceuticals, Inc. Fibrin targeted therapeutics
KR20080067697A (ko) 2005-11-11 2008-07-21 에프. 호프만-라 로슈 아게 응고 인자 ｘａ의 억제제로서 카보사이클릭 융합된사이클릭 아민
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
JP5225098B2 (ja) 2005-12-14 2013-07-03 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
AR058380A1 (es) 2005-12-23 2008-01-30 Bristol Myers Squibb Co Inhibidores del factor viia macrociclicos utiles como anticoagulantes
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
TW200848024A (en) 2007-06-13 2008-12-16 Bristol Myers Squibb Co Dipeptide analogs as coagulation factor inhibitors
ES2380648T3 (es) 2008-03-13 2012-05-17 Bristol-Myers Squibb Company Derivados de piridazina como inhibidores del factor XIA
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8513433B2 (en) 2009-07-02 2013-08-20 Angion Biomedica Corp. Small molecule inhibitors of PARP activity
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
CA2789622C (en) * 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
WO2013009527A2 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Factor ixa inhibitors
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
EP3290413B9 (en) 2011-12-21 2020-04-29 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013111107A1 (en) 2012-01-27 2013-08-01 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
BR112014027952B1 (pt) 2012-05-10 2022-06-21 Bayer Pharma Aktiengesellschaft Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
JP6220786B2 (ja) 2012-07-19 2017-10-25 大日本住友製薬株式会社 １−（シクロアルキルカルボニル）プロリン誘導体
US20140038969A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
DK2880026T3 (en) * 2012-08-03 2017-06-06 Bristol Myers Squibb Co DIHYDROPYRIDON-P1 AS A FACTOR XIA INHIBITORS
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059203A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9708308B2 (en) 2012-12-19 2017-07-18 Merck Sharp Dohme Corp. Factor IXa inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
CN105555767B (zh) 2013-07-23 2018-03-23 拜耳制药股份公司 取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
EP3049408A1 (de) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate
US20160237045A1 (en) 2013-09-26 2016-08-18 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
EP3049394A1 (de) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate als faktor xia modulatoren
WO2015044170A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen
WO2015044172A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate
AR097755A1 (es) 2013-09-26 2016-04-13 Bayer Pharma AG Derivados sustituidos de fenilalanina como moduladores del factor xia
UY35745A (es) 2013-09-26 2015-04-30 Bayer Pharma AG Derivados sustituidos de fenilalanina
EP3049390A1 (de) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate
WO2015047973A1 (en) 2013-09-27 2015-04-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
EP3054944B1 (en) 2013-10-07 2019-12-04 Merck Sharp & Dohme Corp. Factor xia inhibitors
JP6337750B2 (ja) 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
EP3095786A4 (en) 2014-01-14 2017-10-11 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative
ES2893251T3 (es) 2014-01-31 2022-02-08 Bristol Myers Squibb Co Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa
NO2760821T3 (cg-RX-API-DMAC10.html) 2014-01-31 2018-03-10
CN108892661B (zh) 2014-02-07 2023-03-14 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
US9663527B2 (en) 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9944643B2 (en) 2014-02-11 2018-04-17 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3104702B1 (en) 2014-02-11 2022-08-10 Merck Sharp & Dohme LLC Factor xia inhibitors
EP3138839B1 (en) 2014-02-14 2020-10-28 Sichuan Haisco Pharmaceutical Co., Ltd. Pyridone or pyrimidone derivative, preparation method therefor and application thereof
MY199131A (en) 2014-03-07 2023-10-17 Biocryst Pharm Inc Human plasma kallikrein inhibitors
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
US9808445B2 (en) 2014-04-16 2017-11-07 Merck Sharp & Dohme Corp. Factor IXa inhibitors
KR20150136294A (ko) 2014-05-27 2015-12-07 주식회사 레고켐 바이오사이언스 인자 ＸＩａ 억제 활성을 가지는 신규한 화합물
CN106413710A (zh) 2014-05-28 2017-02-15 默沙东公司 因子XIa抑制剂
ES2712886T3 (es) 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (cg-RX-API-DMAC10.html) 2014-10-01 2018-10-20
ES2927307T3 (es) 2014-12-10 2022-11-04 Ono Pharmaceutical Co Derivado de dihidroindolizinona
WO2016205482A1 (en) 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors

Also Published As

Publication number Publication date
TWI703144B (zh) 2020-09-01
BR112016016741A2 (cg-RX-API-DMAC10.html) 2017-08-08
HUE038060T2 (hu) 2018-09-28
LT3099688T (lt) 2017-12-27
TW201615640A (zh) 2016-05-01
PL3099688T3 (pl) 2018-03-30
HRP20172002T1 (hr) 2018-02-09
SMT201800024T1 (it) 2018-03-08
US20170057961A1 (en) 2017-03-02
CN106459051B (zh) 2018-10-16
US20170342071A1 (en) 2017-11-30
EP3099688A1 (en) 2016-12-07
ES2655540T3 (es) 2018-02-20
JP6419836B2 (ja) 2018-11-07
CY1120534T1 (el) 2019-07-10
CN106459051A (zh) 2017-02-22
US10273236B2 (en) 2019-04-30
DK3099688T3 (en) 2018-01-15
CA2937738C (en) 2023-01-17
US20180222907A1 (en) 2018-08-09
PT3099688T (pt) 2018-01-15
JP2017504640A (ja) 2017-02-09
MX2016009385A (es) 2016-09-16
RS56785B1 (sr) 2018-04-30
EA032650B1 (ru) 2019-06-28
SI3099688T1 (sl) 2017-12-29
AR099228A1 (es) 2016-07-06
EA201691561A1 (ru) 2017-01-30
WO2015116882A1 (en) 2015-08-06
UY35972A (es) 2015-07-31
CA2937738A1 (en) 2015-08-06
BR112016016741B1 (pt) 2023-01-17
EP3099688B1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
BR112014017635A2 (cg-RX-API-DMAC10.html)
BR112014017614A2 (cg-RX-API-DMAC10.html)
BR112014017625A2 (cg-RX-API-DMAC10.html)
BR112014017659A2 (cg-RX-API-DMAC10.html)
BR112014017592A2 (cg-RX-API-DMAC10.html)
BR112014017607A2 (cg-RX-API-DMAC10.html)
BR112014017646A2 (cg-RX-API-DMAC10.html)
BR112014017638A2 (cg-RX-API-DMAC10.html)
BR112013027865A2 (cg-RX-API-DMAC10.html)
BR112014017609A2 (cg-RX-API-DMAC10.html)
BR112014017644A2 (cg-RX-API-DMAC10.html)
BR112014017634A2 (cg-RX-API-DMAC10.html)
BR112014017588A2 (cg-RX-API-DMAC10.html)
BR112014013184A8 (cg-RX-API-DMAC10.html)
BR112014017618A2 (cg-RX-API-DMAC10.html)
BR112014017647A2 (cg-RX-API-DMAC10.html)
BR112014017623A2 (cg-RX-API-DMAC10.html)
BR112014017652A2 (cg-RX-API-DMAC10.html)
BR112014017630A2 (cg-RX-API-DMAC10.html)
BR112014017627A2 (cg-RX-API-DMAC10.html)
BR112014017621A2 (cg-RX-API-DMAC10.html)
BR112014017631A2 (cg-RX-API-DMAC10.html)
BR112014017641A2 (cg-RX-API-DMAC10.html)
BR112014017622A2 (cg-RX-API-DMAC10.html)
CH708180A4 (cg-RX-API-DMAC10.html)